Kloss et al. (2018) designed anti-PSMA CAR-T cells to express a dominant negative TGFβ-receptor II (TGFβRII) and investigated the activity of these cells against a prostate cancer cell line and in a mouse model of prostate cancer [172]. Here, FOLH1 is linked to prostate carcinoma.